Suggestions
Greg Brown
Chief Executive Officer at Memgen
Gregory B. Brown, M.D., is the Chief Executive Officer of Memgen, a private biotechnology company focused on developing innovative immuno-oncology drugs. He was appointed to this position on March 17, 2020, and has been a member of Memgen's board of directors since March 2007.12 Under his leadership, Memgen aims to advance its lead program into clinical trials, leveraging promising preclinical data to benefit cancer patients with limited treatment options.1
Professional Background
Dr. Brown has a diverse background that spans the fields of medicine, finance, and biotechnology:
- Medical Training: He is trained as a thoracic and vascular surgeon and has practiced in a community setting. His medical education includes an M.D. from SUNY Upstate Medical Center and a BA from Yale University.23
- Investment Experience: He co-founded HealthCare Royalty Partners (HCR), where he currently serves as Vice Chairman and a member of the Senior Advisor Board. His previous roles include being a partner at Paul Capital Partners and co-head of investment banking at Adams, Harkness & Hill.13
- Board Memberships: Dr. Brown has served on the boards of numerous public and private life science companies, including Aquestive Therapeutics and Caladrius Biosciences.12
Education
Dr. Brown holds an MBA from Harvard Business School, complementing his medical degree and undergraduate education at Yale.23
Personal Life
He is married to Iris DeMent, an accomplished singer-songwriter.
Dr. Brown's extensive experience in both clinical practice and the financial aspects of biotechnology positions him as a significant leader in the field, driving Memgen's mission forward in the competitive landscape of cancer therapeutics.
Highlights


